N. Senthivel

To assess the prevalence and types of lipid abnormalities, analyze the rationalein the drug therapy and drug interactions in the drug therapy. Each patient’s medication profile was reviewed and patients who met the inclusion criteria were briefed on the study. The data from medical charts of all the cases with lipid abnormality were recorded during ward rounds. The study population included patients with primary dyslipidemia (38.8%) and secondary dyslipidemia (61.2%). The major concomitant disease was systemic hypertension followed by Diabetes Mellitus. Majority of the patients were in non CHD category. 88.7% of non CHD patients had 2+ risk factors and 11.3% had 1 risk factor. The non CHD group were subjected for estimation of 10 year risk percentage for having CHD using Framingham’s scale in which 92% of non CHD patients had ≤ 20% ten year risks for having CHD. The drug interactions with lipid lowering agents were 33.3% and without lipid lowering agents were 66.7%. The major drug interactions with lipid lowering agents were high. Conclusion: Results revealed that Diabetes, Thyroid Disorders, Nephrotic Disorders are responsible for elevation of lipid profiles. Some dyslipidemias appear to be refractory to drug treatment in the presence of an ongoing unrecognized secondary cause.